Beijing Center

    After purchasing 53.80% equities of DHY&CO., LTD, Yifan formally enters into the field of macromolecular innovative biologics. Through purchasing DHY’s equity, Yifan has owned two advanced technological R&D platform with one DikineTM: Dimeric Cytokine Platform and another ITabTM: Immuno-antibody Platform, in which several macromolecular biologics has been in international clinical II and III. Yifan is the first domestic company whose innovative biologics entered into phase II and III in America. All solutions of products under research and the listed products in DHY are produced by Generon (Beijing).